From Name:
From Email:
To Name:
To Email:

Optional Message:


New combo lung cancer therapy improves survival over single-line treatment

from e! Science News

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer, according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals. The phase 2 results show that the combination of entinostat and erlotinib was more effective in treating NSCLC in patients with elevated levels of the molecular cancer marker E-cadherin than using erlotinib alone. University of Colorado Cancer Center researchers, who are faculty at the University of Colorado School of Medicine, were the first to identify elevated E-cadherin as a targetable cancer marker, the first to develop the biomarker tumor testing process for elevated E-cadherin and the first to test the combined therapy. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063